Clinical and Experimental Nephrology

, Volume 22, Issue 1, pp 15–27 | Cite as

Impact of low-density lipoprotein cholesterol on decline in estimated glomerular filtration rate in apparently healthy young to middle-aged working men

  • Akihiro KumaEmail author
  • Bungo Uchino
  • Yoko Ochiai
  • Masatoshi Kawashima
  • Kazuhiko Enta
  • Masahito Tamura
  • Yutaka Otsuji
  • Akihiko Kato
Original article



It remains to be fully clarified whether there is a relationship between uncontrolled dyslipidemia and decline in estimated glomerular filtration rate (eGFR) in the general population. Therefore, this study’s aim was to test the association of dyslipidemia with changes in eGFR in apparently healthy working men.


We retrospectively examined the annual medical check-up list of 14,510 male workers aged 20–60 years with eGFR ≥ 60 mL/min/1.73 m2 at baseline, and then evaluated the association of the changes in the check-up parameters with a decline in eGFR during the 5-year observation period.


Mean age and eGFR were 38.5 years and 82.3 mL/min/1.73 m2 at baseline, respectively. Evaluated low-density lipoprotein cholesterol (LDL-C) (≥140 mg/dL) was a strong indicator of CKD development in participants (basal eGFR 60–90 mL/min/1.73 m2) without hypertension [odds ratio (95% confidence interval): 1.46 (1.12–1.90)] or diabetes mellitus (DM) [1.49 (1.23–1.82)]. When LDL-C normalized under 140 mg/dL during follow-up, the decline in eGFR was smaller in non-hypertensive participants [−5.9 (−14.4 to −0.9) vs −13.4 (−18.4 to −4.5) mL/min/1.73 m2, p < 0.05]. There was an inverse correlation between change of LDL-C and decline in eGFR (p for trend <0.001).


Increased LDL-C levels are associated with the development of incident CKD and eGFR decline in young to middle-aged working men without hypertension and/or DM.


Metabolic syndrome Dyslipidemia Chronic kidney disease Health check-up Occupational health 



We thank all staffs at the Health Care Center in Central Japan Railway Company and at the Health Promotion Center in Yamaha Motor Co., Ltd., for supplying annual health check-up data.

Compliance with ethical standards

Conflict of interest

The authors have declared that no conflict of interest exists.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee (Hamamatsu University School of Medicine, approval number E15-289) at which the studies were conducted and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

We provided all individual participants a means to opt out in this study.

Supplementary material

10157_2017_1407_MOESM1_ESM.pdf (2.6 mb)
Supplementary material 1 (PDF 2712 KB)


  1. 1.
    Thomas G, Sehgai AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364–73.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ninomiya T, Kiyohara Y, Kubo M, Yonemoto Y, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: The Hisayama Study. Am J Kidney Dis. 2006;48:383–91.CrossRefPubMedGoogle Scholar
  3. 3.
    O’Seaghdha CM, Hwang SJ, Upadhyay A, Meigs JB, Fox CS. Predictors of incident albuminuria in the Framingham Offspring cohort. Am J Kidney Dis. 2010;56:852–60.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Tsuruya K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66:972–83.CrossRefPubMedGoogle Scholar
  5. 5.
    van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.CrossRefPubMedGoogle Scholar
  6. 6.
    Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349–60.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kidney Disease. Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. 2013; Suppl 3:259–305.Google Scholar
  9. 9.
    Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMedGoogle Scholar
  10. 10.
    D’Adamo E, Santoro N, Caprio S. Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. Endocrinol Metab Clin N Am. 2009;38:549–63.CrossRefGoogle Scholar
  11. 11.
    Vrdoljak A, Ivkovic V, Karanovic S, Dika Z, Domislovic V, Dapic K, et al. Glomerular hyperfiltration as a risk factor for renal impairment and hypertension in apparently healthy subjects. J Hypertens. 2016;34(Suppl 2):e19.CrossRefGoogle Scholar
  12. 12.
    Moriya T, Tanaka S, Sone H, Ishibashi S, Matsunaga S, Ohashi Y, et al. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study. J Diabetes Complicat. 2016. doi: 10.1016/j.jdiacomp.2016.06.020. Accessed 29 Jun 2016.Google Scholar
  13. 13.
    Matsumoto I, Miyake Y, Mizukawa M, Takagi Y. Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J. 2011;75:905–10.CrossRefPubMedGoogle Scholar
  14. 14.
    Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet. 2016;388:276–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24:979–86.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Keys A, Menotti A, Aravanis C, Blackburn H, Djordevic BS, Buzina R, et al. The seven countries study: 2289 deaths in 15 years. Prev Med. 1984;13:141–54.CrossRefPubMedGoogle Scholar
  17. 17.
    Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezemitibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid loweiring with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448–54.CrossRefPubMedGoogle Scholar
  19. 19.
    Brenner BM, Cooper ME, Zeeuw DD, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Niculescu LS, Sanda GM, Sima AV. HDL inhibits endoplasmic reticulum stress by stimulating apoE and CETP secretion from lipid-loaded macrophages. Biochem Biophys Res Commun. 2013;434:173–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546–51.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nistala R, Whaley-Connel A, Sowers JR. Redox control of renal function and hypertension. Antioxid Redox Signal. 2008;10:2047–89.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nakano T, Ninomiya T, Sumiyoshi S, Onimaru M, Fujii H, Itabe H, et al. Chronic kidney disease is associated with neovascularization and intraplaque hemorrhage in coronary atherosclerosis in elders: results from the Hisayama Study. Kidney Int. 2013;84:373–80.CrossRefPubMedGoogle Scholar
  24. 24.
    Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301.CrossRefPubMedGoogle Scholar
  25. 25.
    Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Hou X, Wang C, Zhang X, Zhao X, Wang Y, Li C, et al. Triglyceride levels are closely associated with mild decline in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. PLoS ONE. 2014;9:e106778.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, et al. Plasma lipoproteins and apolopoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2005;112:3058–65.CrossRefPubMedGoogle Scholar
  28. 28.
    Vidt DG, Ridker PM, Monyak JT, Schreiber MJ, Cressman MD. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statin in prevention: an intervention trial evaluating rousuvastatin). Clin Ther. 2011;33:717–25.CrossRefPubMedGoogle Scholar
  29. 29.
    Rahman M, Yang W, Akkina S, Alpher A, Anderson AH, Appel LJ, et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin J Am Soc Nephrol. 2014;9:1190–8.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Miyamoto Y, Yoshimasa Y, et al. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and incidence of cardiovascular disease in an urban Japanese cohort study: the Suita study. Atherosclerosis. 2009;203:587–92.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2017

Authors and Affiliations

  • Akihiro Kuma
    • 1
    • 2
    • 3
    Email author
  • Bungo Uchino
    • 4
  • Yoko Ochiai
    • 4
  • Masatoshi Kawashima
    • 3
  • Kazuhiko Enta
    • 3
  • Masahito Tamura
    • 5
  • Yutaka Otsuji
    • 1
  • Akihiko Kato
    • 2
  1. 1.Second Department of Internal Medicine, School of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
  2. 2.Blood Purification UnitHamamatsu University HospitalHamamatsuJapan
  3. 3.Health Care CenterCentral Japan Railway CompanyShizuokaJapan
  4. 4.Health Promotion CenterYamaha Motor Co., Ltd.IwataJapan
  5. 5.Kidney CenterUniversity Hospital of Occupational and Environmental HealthKitakyushuJapan

Personalised recommendations